Study finds elevated levels of cell-free DNA in first trimester do not predict preeclampsia

In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Dallas, Texas, researchers will report findings that indicate that elevated levels of cell-free DNA in the first trimester do not predict the subsequent development of preeclampsia.

"I wanted to identify if elevated levels of cell-free fetal DNA in maternal blood early in pregnancy could identify women at risk for the subsequent development of preeclampsia. I found that there is no significant difference in levels of total or free fetal DNA in the in women who subsequently develop preeclampsia," said Bob Silver, MD, with the University of Utah Health Sciences Center and Intermountain Healthcare, , in Salt Lake City, Utah. Silver conducted the study, entitled First Trimester Free Fetal DNA in The Maternal Circulation as a Predictor of .

More information: A copy of the abstract is available at www.smfmnewsroom.org/annual-me… 1-meeting-abstracts/

Provided by Society for Maternal-Fetal Medicine

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pregnancy outcome affected by immune system genes

Oct 25, 2010

A team of researchers, led by Ashley Moffett, at the University of Cambridge, United Kingdom, has shed new light on genetic factors that increase susceptibility to and provide protection from common disorders of pregnancy, ...

Recommended for you

Face transplants change lives, identity

15 hours ago

Patients are prepared to take significant risks in order to be considered for a face transplant, says Dr David Koppel, director of the largest craniofacial unit in the UK and Honorary Clinical Associate Professor ...

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

User comments